siRNA (small interfering RNA) is a class of double-stranded RNA molecules typically 21–23 nucleotides in length. Through the RNA interference (RNAi) pathway, siRNA specifically guides the degradation of target mRNA, leading to sequence-specific gene silencing. As one of the most mature small nucleic acid therapeutic platforms, siRNA has demonstrated significant therapeutic potential across multiple disease areas and has become a key modality in nucleic acid drug development.
Leveraging established oligonucleotide chemistry platforms and robust quality control systems, BiOligo provides high-purity siRNA products from nmol to kilogram scale, supporting RNAi therapeutic development across the R&D lifecycle. With flexible options for diverse chemical modifications and molecular conjugations, we offer an integrated oligonucleotide synthesis solution to accelerate RNAi therapeutic development.
Service Specifications
| Product Name | Length | Scale | Purification | Quality Control |
| Custom siRNA Synthesis | 19–30 nt | 2 OD to kilogram scale | RNase-free HPLC Purity ≥90% | HPLC MASS Additional QC requirements |
* For larger-scale production or other customized requirements, please contact blg-mkt@bioligo.com for further consultation.
Delivery Timeline
| OD level | 5–8 days | |
| mg scale | 2 weeks | |
g scale | 2-4 weeks | |
| Above gram scale | Upon consultation | |
Modification Options
Supports over 200+ chemical modifications, including MOE, 2′-O-Methyl, 2′-Fluoro, phosphorothioate (PS), and more.
.png)
Conjugation Options
Supports conjugation with GalNAc, AVβ6, antibodies, cholesterol, and other functional moieties; enables dual-target siRNA design and synthesis.
Gram-Scale Quality Reports
Quality Testing Overview
Test Item | Analytical Method | Representative Results | Value |
Appearance | Visual Inspection | White Solid | — |
Molecular Weight | LC-MS | Within ±0.05% of the target molecular weight | High molecular weight accuracy |
Purity & Related Substances (Non-Denaturing) | IP-RP-HPLC | 96%–98.27%; AS: 1.39%, SS: 0.11% | More reliable drug activity and closer alignment with clinical-stage performance |
Purity & Related Substances (Denaturing) | IP-RP-HPLC | 90.52% | More reliable drug activity and closer alignment with clinical-stage performance |
Water Content | KF | 4.007% | High drug yield and cost-effectiveness |
pH | / | 6.85 | Close to physiological pH, helping minimize adverse effects |
Sodium Content | IC/ICP-MS | 6.0% | — |
Residual Solvents | GC | 0.019% | Reduced risk of toxic effects |
Bacterial Endotoxins | ChP/USP | 0.01–0.1 EU/mg | Low endotoxin level, helping reduce immune responses and drug clearance |
Content by Weight | / | 95.974% | High drug yield and cost-effectiveness |
Reference Reports
 |  Analysis.png) |
QC Report Summary | Mass |
 |  |
Non-denaturing HPLC | Denaturing Duplex UPLC |
 |  |
Water Content | Sodium Content |
 |  |
Residual Solvents | Endotoxin Report |
